ライフサイエンスコーパス: Waldenstrom

1 Waldenstrom macroglobulinemia (WM) cells present with in

2 Waldenstrom macroglobulinemia (WM) is a B-cell disorder

3 Waldenstrom macroglobulinemia (WM) is a B-cell malignanc

4 Waldenstrom macroglobulinemia (WM) is a B-cell malignanc

5 Waldenstrom macroglobulinemia (WM) is a B-cell neoplasm

6 Waldenstrom macroglobulinemia (WM) is a distinct B-cell

7 Waldenstrom macroglobulinemia (WM) is a distinct B-cell

8 Waldenstrom macroglobulinemia (WM) is a distinct B-cell

9 Waldenstrom macroglobulinemia (WM) is a lymphoid neoplas

10 Waldenstrom macroglobulinemia (WM) is a proliferative di

11 Waldenstrom macroglobulinemia (WM) is a rare, lymphoplas

12 Waldenstrom macroglobulinemia (WM) is an incurable low-g

13 Waldenstrom macroglobulinemia (WM) is an incurable low-g

14 Waldenstrom macroglobulinemia (WM) is an incurable low-g

15 Waldenstrom macroglobulinemia (WM) is an incurable lymph

16 Waldenstrom macroglobulinemia (WM) is characterized by w

17 Waldenstrom macroglobulinemia (WM), a distinctive subtyp

18 Waldenstrom macroglobulinemia (WM), an IgM-associated ly

19 Waldenstrom macroglobulinemia (WM), which has an immunog

20 Waldenstrom macroglobulinemia is a distinct low-grade ly

21 Waldenstrom macroglobulinemia is a similar disease with

22 Waldenstrom's macroglobulinemia (WM) is a distinct clini

23 Waldenstrom's macroglobulinemia (WM) is characterized by

24 Waldenstrom's macroglobulinemia is an incurable, IgM-sec

25 (n = 4, 22%), multiple myeloma (n = 2, 11%), Waldenstrom's macroglobulinemia (n = 2, 11%), extranodal

26 Risks for non-Hodgkin lymphoma (n = 1359), Waldenstrom macroglobulinemia (n = 165), and cryoglobuli

27 ic leukemia (Richter transformation; n = 7), Waldenstrom macroglobulinemia (n = 4), and marginal zone

28 d in 17 patients (relative risk [RR], 14.8), Waldenstrom macroglobulinemia in 6 (RR, 262), primary am

29 cil to Fludarabine in Patients With Advanced Waldenstrom Macroglobulinemia) was undertaken in 101 cen

30 a (MM) than chronic lymphocytic leukemia and Waldenstrom macroglobulinaemia; that T cells are more pr

31 from patients with mantle cell lymphoma and Waldenstrom macroglobulinemia.

32 ic leukemia (CLL), mantle cell lymphoma, and Waldenstrom macroglobulinemia.

33 ificance (MGUS), multiple myelomas (MM), and Waldenstrom's macroglobulinemias (WM) using protein macr

34 ry, acute myeloid leukemia/myelofibrosis and Waldenstrom macroglobulinemia/myeloma.

35 Multiple myeloma and Waldenstrom macroglobulinemia are incurable hematologic

36 enetic abnormalities in multiple myeloma and Waldenstrom macroglobulinemia have implications for dise

37 ples from patients with multiple myeloma and Waldenstrom's macroglobulinemia without invasive fungal

38 ght-chain amyloidosis, multiple myeloma, and Waldenstrom macroglobulinemia.

39 CD56(-) MM cell lines, as well as a CD56(-) Waldenstrom's macroglobulinemia cell line.

40 B-cell morphology revealed that plasma cell Waldenstrom macroglobulinemia samples most closely resem

41 dults aged 18 years and older with confirmed Waldenstrom's macroglobulinaemia, refractory to rituxima

42 inemia that can be useful in differentiating Waldenstrom's macroglobulinemia and non-IgM LPL from B-c

43 For Waldenstrom macroglobulinemia (WM), a distinct subtype o

44 cal evaluation of investigational agents for Waldenstrom macroglobulinemia (WM) has been limited by t

45 The genetic basis for Waldenstrom macroglobulinemia (WM) remains to be clarifi

46 Rituximab is an important therapeutic for Waldenstrom's macroglobulinemia (WM).

47 In the era of widespread rituximab use for Waldenstrom's macroglobulinaemia, new treatment options

48 utation in benign monoclonal IgM gammopathy, Waldenstrom's macroglobulinemia, and diffuse large B cel

49 rapeutic targeting, such as interleukin-6 in Waldenstrom macroglobulinemia.

50 tigate and report its aberrant activation in Waldenstrom macroglobulinemia (WM).

51 ations including MYD88, CXCR4, and ARID1A in Waldenstrom macroglobulinemia (WM).

52 atic mutations in MYD88 (L265P) and CXCR4 in Waldenstrom macroglobulinemia (WM).

53 mbination led to synergistic cytotoxicity in Waldenstrom macroglobulinemia (WM) cells that was mediat

54 gnificance of IL-21 has not been examined in Waldenstrom macroglobulinemia (WM), a B-cell lymphoma ch

55 t of rapamycin (mTOR) complex 1 inhibitor in Waldenstrom macroglobulinemia (WM).

56 nical models, the role of these molecules in Waldenstrom macroglobulinemia (WM) remains poorly unders

57 hemokine receptor type 4 (CXCR4) mutation in Waldenstrom macroglobulinemia (WM), a marker of tumor ag

58 8 (L265P) is a recurring somatic mutation in Waldenstrom's macroglobulinemia (WM).

59 has revealed recurring somatic mutations in Waldenstrom macroglobulinemia (WM).

60 derstand the molecular changes that occur in Waldenstrom macroglobulinemia (WM), we employed antibody

61 portant information on the cell of origin in Waldenstrom macroglobulinemia (WM), a longstanding puzzl

62 atment-related peripheral neuropathy (PN) in Waldenstrom's macroglobulinemia (WM).

63 265P somatic mutation is highly prevalent in Waldenstrom macroglobulinemia (WM) and supports malignan

64 XCR4(WHIM) mutations are highly prevalent in Waldenstrom's macroglobulinemia.

65 ironment) that regulate tumor progression in Waldenstrom macroglobulinemia.

66 igh response rates and durable remissions in Waldenstrom macroglobulinemia (WM) that are impacted by

67 study examining fludarabine and rituximab in Waldenstrom macroglobulinemia (WM).

68 n, as well as NF-kappaB nuclear staining, in Waldenstrom's macroglobulinemia cells expressing MYD88 L

69 ictate clinical presentation and survival in Waldenstrom macroglobulinemia (WM).

70 r approach and its use has been validated in Waldenstrom macroglobulinemia (WM), where bortezomib has

71 ell lymphoproliferative disorders, including Waldenstrom macroglobulinemia (WM) and chronic lymphocyt

72 ic of several B cell malignancies, including Waldenstrom macroglobulinemia (WM), where elevated IgM i

73 of patients with lymphoplasmacytic lymphoma (Waldenstrom macroglobulinemia [WM]), being either absent

74 Adjusted P values for non-Hodgkin lymphoma, Waldenstrom macroglobulinemia, cryoglobulinemia, and thy

75 = 2.9; 1.9-4.3), lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia (LPL/WM; RR = 4.0; 1.5-11)

76 ic and molecular signatures of the malignant Waldenstrom clone.

77 significance (MGUS), multiple myeloma (MM), Waldenstrom macroglobulinemia (WM) and light chain AL am

78 Observations: Waldenstrom macroglobulinemia remains a rare, incurable

79 or kappaB activity and is present in >90% of Waldenstrom macroglobulinemia (WM) patients.

80 ype diffuse large B-cell lymphoma and 90% of Waldenstrom macroglobulinemia, making it conceptually at

81 Familial aggregation of Waldenstrom macroglobulinemia (WM) and related B-cell di

82 Familial aggregation of Waldenstrom macroglobulinemia (WM) cases, and the cluste

83 both in the understanding of the biology of Waldenstrom macroglobulinemia (WM) and in therapeutic op

84 thy of uncertain significance, and 1 case of Waldenstrom's macroglobulinemia.

85 Multilevel genetic characterization of Waldenstrom macroglobulinemia (WM) is required to improv

86 he bone marrow biopsy specimen, diagnosis of Waldenstrom macroglobulinemia was established, and compu

87 of MyD88, which is mutated in a fraction of Waldenstrom macroglobulinemia.

88 e of a 77-year-old white man with history of Waldenstrom's macroglobulinemia transforming to large B-

89 ormation about the molecular pathogenesis of Waldenstrom macroglobulinemia (WM) has significantly adv

90 the advances observed in the pathogenesis of Waldenstrom macroglobulinemia.

91 ymphoma overall, and a 3-fold higher risk of Waldenstrom macroglobulinemia, a low-grade lymphoma.

92 Profiling performed after separation of Waldenstrom macroglobulinemia samples into populations w

93 A whole exome-sequencing study of Waldenstrom macroglobulinemia (WM) suggested a high freq

94 ed as appropriate agents in the treatment of Waldenstrom macroglobulinemia (WM), a lymphoplasmacytic

95 Current information on Waldenstrom macroglobulinemia (WM) is based on retrospec

96 nsus panels of the International Workshop on Waldenstrom's Macroglobulinemia (IWWM).

97 patients with heavily pretreated MM (22) or Waldenstrom macroglobulinemia (3) were administered seli

98 (IgM) class, which progresses to lymphoma or Waldenstrom macroglobulinemia, whereas IgA and IgG MGUS

99 as splenic marginal zone B-cell lymphoma or Waldenstrom macroglobulinemia.

100 ificance, smoldering plasma cell myeloma, or Waldenstrom macroglobulinemia.

101 Following profiling, Waldenstrom macroglobulinemia samples clustered with chr

102 inostat in patients with relapsed/refractory Waldenstrom macroglobulinemia (WM).

103 rolimus in patients with relapsed/refractory Waldenstrom macroglobulinemia (WM).

104 tuximab in patients with relapsed/refractory Waldenstrom macroglobulinemia (WM).

105 had heavily pretreated, rituximab-refractory Waldenstrom's macroglobulinaemia.

106 had heavily pretreated, rituximab-refractory Waldenstrom's macroglobulinaemia.

107 mumab monotherapy for untreated and relapsed Waldenstrom's macroglobulinaemia.

108 ho were diagnosed with untreated or relapsed Waldenstrom's macroglobulinaemia and required treatment,

109 ytic lymphoma (LPL), including IgM-secreting Waldenstrom macroglobulinemia (WM).

110 ion and survival of patients with smoldering Waldenstrom macroglobulinemia (SWM).

111 ing thalidomide and rituximab in symptomatic Waldenstrom macroglobulinemia (WM) patients naive to eit

112 4 years), 34 (71%) progressed to symptomatic Waldenstrom macroglobulinemia (WM) requiring treatment,

113 the International Prognostic Scoring System Waldenstrom Macroglobulinaemia, median number of previou

114 ays normalized once the transcriptome of the Waldenstrom B-cell clone was compared with its normal ph

115 Interestingly, the transcriptome of the Waldenstrom B-cell clone was highly different than that

116 four small lymphocytic lymphomas (SLL), two Waldenstrom's macroglobulinemias (WM), and one marginal

117 en with systemic treatment of the underlying Waldenstrom macroglobulinemia, the visual prognosis was

118 BDR) in patients with symptomatic, untreated Waldenstrom macroglobulinemia (WM).

119 early universal in multiple myeloma, whereas Waldenstrom macroglobulinemia generally does not harbor

120 with splenic marginal zone lymphoma, 29 with Waldenstrom macroglobulinemia, and 57 with B-cell chroni

121 ryopyrin-associated periodic disease, 9 with Waldenstrom disease, and 10 with chronic spontaneous urt

122 t(9;14)(p13;q32), previously associated with Waldenstrom's macroglobulinemia and lymphoplasmacytoid l

123 lly with thymoma, a myopathy associated with Waldenstrom's macroglobulinemia, Lambert-Eaton myastheni

124 Four patients (8 eyes) with Waldenstrom macroglobulinemia and serous retinal detachm

125 found among RFs from HID or individuals with Waldenstrom's macroglobulinemia who do not have joint di

126 elated clones in the blood of a patient with Waldenstrom macroglobulinemia (WM) indicates the functio

127 A monoclonal IgM from a patient with Waldenstrom's macroglobulinemia hydrolyzed Abeta40 at th

128 Treatment options for patients with Waldenstrom macroglobulinemia (WM) and closely related d

129 YD88 L265P somatic mutation in patients with Waldenstrom macroglobulinemia (WM) and provide insight i

130 The survival of patients with Waldenstrom macroglobulinemia (WM) varies enormously.

131 resent in approximately 95% of patients with Waldenstrom macroglobulinemia (WM), as well as other B-c

132 eviously untreated symptomatic patients with Waldenstrom macroglobulinemia (WM), most of which were o

133 eviously untreated symptomatic patients with Waldenstrom macroglobulinemia (WM).

134 brand syndrome is described in patients with Waldenstrom macroglobulinemia (WM).

135 The records of patients with Waldenstrom macroglobulinemia and OCT documentation of s

136 of 6q is identified in 50% of patients with Waldenstrom macroglobulinemia, however.

137 erapeutic treatment option for patients with Waldenstrom's macroglobulinaemia, especially those with

138 emotherapeutics, is needed for patients with Waldenstrom's macroglobulinaemia.

139 esponses in previously treated patients with Waldenstrom's macroglobulinaemia.

140 malignant B cells derived from patients with Waldenstrom's macroglobulinemia (WM).

141 in tumor samples from 49 of 54 patients with Waldenstrom's macroglobulinemia and in 3 of 3 patients w

142 Two patients with Waldenstrom's macroglobulinemia and one patient with HD

143 red normal tissue samples from patients with Waldenstrom's macroglobulinemia or non-IgM LPL and in B

144 commonly recurring mutation in patients with Waldenstrom's macroglobulinemia that can be useful in di

145 of ibrutinib in 63 symptomatic patients with Waldenstrom's macroglobulinemia who had received at leas

146 In addition, 2 of 3 patients with Waldenstrom's macroglobulinemia who had wild-type MYD88

147 Among the patients with Waldenstrom's macroglobulinemia, a somatic variant (T-->

148 of bone marrow LPL cells in 30 patients with Waldenstrom's macroglobulinemia, with paired normal-tiss

149 at we previously analyzed from patients with Waldenstrom's macroglobulinemia.

150 ponses, and safe in pretreated patients with Waldenstrom's macroglobulinemia.

151 d lymphoplasmacytic lymphoma with or without Waldenstrom's macroglobulinemia (10).